Replies to post #988 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>The remaining defects are rare and generally transmitted as autosomal recessive disorders, with prevalences ranging from approximately 1 in 500,000 to 1 in 2 million<

Monday’s CC gave the actual number of individuals in the indication that GTC and LFB plan to pursue—severe hemophilia with inhibitors: 21,000 in the U.S. and 36,000 in Europe. This works out to about 1 case in every 7,000 males.

[DewDiligence]

>I haven't heard of the other product, only NovoSeven.<

There is no other recombinant factor VIIa; the others are derived from plasma and are small-selling products.